HK1190064A1 - Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate - Google Patents

Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate

Info

Publication number
HK1190064A1
HK1190064A1 HK14102832.2A HK14102832A HK1190064A1 HK 1190064 A1 HK1190064 A1 HK 1190064A1 HK 14102832 A HK14102832 A HK 14102832A HK 1190064 A1 HK1190064 A1 HK 1190064A1
Authority
HK
Hong Kong
Prior art keywords
tenovofir
rilpivirin
hcl
therapeutic compositions
disoproxil fumarate
Prior art date
Application number
HK14102832.2A
Other languages
English (en)
Chinese (zh)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1190064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1190064A1 publication Critical patent/HK1190064A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK14102832.2A 2010-11-19 2014-03-21 Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate HK1190064A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Publications (1)

Publication Number Publication Date
HK1190064A1 true HK1190064A1 (en) 2014-06-27

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106347.0A HK1206592A1 (en) 2010-11-19 2014-03-21 Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate
HK14102832.2A HK1190064A1 (en) 2010-11-19 2014-03-21 Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15106347.0A HK1206592A1 (en) 2010-11-19 2014-03-21 Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate

Country Status (35)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2640362B2 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN106511357A (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA025852B1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (2) HK1206592A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20211657A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201912527XA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921003A (zh) * 2015-06-30 2018-04-17 吉利德科学公司 药物制剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308136T3 (es) 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
MX347512B (es) 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.
BR112014003420B1 (pt) 2011-08-16 2021-07-20 Gilead Sciences, Inc Hemifumarato de tenofovir alafenamida. composição, seus métodos de preparação e uso
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
PE20181207A1 (es) * 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
EP3645003A4 (en) * 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
ES2308136T3 (es) 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
EA013686B1 (ru) 2004-09-02 2010-06-30 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2625776A1 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
BRPI0620705A2 (pt) 2005-12-14 2011-11-22 Cipla Ltd formulação farmacêutica em uma forma única de dosagem unitária, produto farmacêutico, uso de uma formulação farmacêutico e uso de um inibidor de transcriptase-reversa de nucleosìdeo ou derivado fisiologicamente funcional do mesmo e um inibidor de transcriptase-reversa de nucleotìdeo ou derivado fisiologicamente funcional do mesmo
ES2601820T3 (es) * 2007-02-23 2017-02-16 Gilead Sciences, Inc. Moduladores de propiedades terapéutica de las farmacocinéticas
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
CN101778855A (zh) 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
KR101738325B1 (ko) 2009-02-06 2017-05-19 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
KR101818779B1 (ko) 2009-09-21 2018-01-15 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX347512B (es) 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921003A (zh) * 2015-06-30 2018-04-17 吉利德科学公司 药物制剂

Also Published As

Publication number Publication date
KR20140037799A (ko) 2014-03-27
TWI556840B (zh) 2016-11-11
EA201390651A1 (ru) 2013-11-29
TW201238612A (en) 2012-10-01
AU2016208417B2 (en) 2018-04-05
SG190333A1 (en) 2013-06-28
AP2013006931A0 (en) 2013-06-30
CN103491948B (zh) 2016-11-02
BR112013012245A2 (pt) 2016-08-09
SG10201509521WA (en) 2015-12-30
AU2011329642A1 (en) 2013-05-02
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
KR101923103B1 (ko) 2018-11-28
ZA201304481B (en) 2022-03-30
EP2826466A1 (en) 2015-01-21
JP2014500261A (ja) 2014-01-09
EP2640362B2 (en) 2021-12-01
EP2640362B1 (en) 2014-09-10
US10857102B2 (en) 2020-12-08
PT2640362E (pt) 2014-11-28
JP6138851B2 (ja) 2017-05-31
ME01980B (me) 2015-05-20
HRP20140946T1 (hr) 2015-02-13
SG10201912527XA (en) 2020-02-27
SMT201400150B (it) 2015-01-15
IL226300B (en) 2019-05-30
BR112013012245B1 (pt) 2022-09-27
PE20170521A1 (es) 2017-05-27
RS53691B1 (en) 2015-04-30
ECSP13012700A (es) 2013-08-30
AR123409A2 (es) 2022-11-30
CL2013001402A1 (es) 2013-12-27
MA34735B1 (fr) 2013-12-03
PL2640362T5 (pl) 2022-05-02
ES2524408T3 (es) 2014-12-09
HK1206592A1 (en) 2016-01-15
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
CA2818097C (en) 2019-07-30
DK2640362T3 (en) 2014-12-01
AU2018202635A1 (en) 2018-05-10
PE20140163A1 (es) 2014-02-08
MX2013005669A (es) 2013-11-04
EP2640362A1 (en) 2013-09-25
AP3816A (en) 2016-09-30
NZ610729A (en) 2015-10-30
CR20130293A (es) 2013-10-03
AR084500A1 (es) 2013-05-22
MY185604A (en) 2021-05-25
EA025852B1 (ru) 2017-02-28
UA114075C2 (xx) 2017-04-25
CN103491948A (zh) 2014-01-01
AU2016208417A1 (en) 2016-08-18
PE20211657A1 (es) 2021-08-24
JP2015131853A (ja) 2015-07-23
MX347512B (es) 2017-04-28
CO6761300A2 (es) 2013-09-30
ES2524408T5 (es) 2022-04-25
CA2818097A1 (en) 2012-05-24
US20130243857A1 (en) 2013-09-19
WO2012068535A1 (en) 2012-05-24
EA201691695A1 (ru) 2017-11-30
PL2640362T3 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
HK1190064A1 (en) Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2646468A4 (en) ANTI-NGF COMPOSITIONS AND THEIR USE
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
HK1201454A1 (en) Therapeutic agents and uses thereof
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
EP2588127A4 (en) DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
PT2521445T (pt) Formulação e utilização da mesma
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201011411D0 (en) Therapeutic compounds and their use
PL2565182T3 (pl) Nowa pochodna amidu i jej zastosowanie jako leku
EP2694587A4 (en) PREPARATIONS OF BIOCOMPATIBLE POLYCAPROLACTONE FUMARATE
SG10201602111VA (en) Formulations Comprising Methylthioninium Chloride
EP2660249A4 (en) PEPTIDE DERIVATIVE AND USE THEREOF
HK1182712A1 (en) Therapeutic agents 976 976
SI2640362T2 (sl) Terapevtski sestavki, ki vsebujejo rilpivirin hcl in tenovofir disoproksil
ZA201209021B (en) Therapeutic peptide composition and method
GB201003741D0 (en) Methods and therapeutic compositions
AU332227S (en) Therapeutic pillow
GB201006380D0 (en) Excipients and their use
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB201016149D0 (en) Effective and essential bedding and table clothing
GB201012660D0 (en) Inhaler and formulation

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)